MX2021014170A - Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas. - Google Patents
Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas.Info
- Publication number
- MX2021014170A MX2021014170A MX2021014170A MX2021014170A MX2021014170A MX 2021014170 A MX2021014170 A MX 2021014170A MX 2021014170 A MX2021014170 A MX 2021014170A MX 2021014170 A MX2021014170 A MX 2021014170A MX 2021014170 A MX2021014170 A MX 2021014170A
- Authority
- MX
- Mexico
- Prior art keywords
- paraproteinemic
- complement system
- neuropathies
- treating
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014170A true MX2021014170A (es) | 2022-01-04 |
Family
ID=67385155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014170A MX2021014170A (es) | 2019-05-21 | 2020-05-21 | Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas. |
| MX2025014486A MX2025014486A (es) | 2019-05-21 | 2021-11-18 | Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025014486A MX2025014486A (es) | 2019-05-21 | 2021-11-18 | Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20250066460A1 (enExample) |
| EP (2) | EP3972643B1 (enExample) |
| JP (3) | JP7607590B2 (enExample) |
| KR (1) | KR20220010505A (enExample) |
| CN (2) | CN118021970A (enExample) |
| AU (1) | AU2020279543A1 (enExample) |
| BR (1) | BR112021023198A2 (enExample) |
| CA (1) | CA3138401A1 (enExample) |
| DK (1) | DK3972643T3 (enExample) |
| EA (1) | EA202193189A1 (enExample) |
| ES (1) | ES3035736T3 (enExample) |
| FI (1) | FI3972643T3 (enExample) |
| GB (1) | GB2584105B (enExample) |
| HU (1) | HUE072743T2 (enExample) |
| IL (1) | IL288010A (enExample) |
| LT (1) | LT3972643T (enExample) |
| MA (1) | MA71752A (enExample) |
| MX (2) | MX2021014170A (enExample) |
| PL (1) | PL3972643T3 (enExample) |
| PT (1) | PT3972643T (enExample) |
| SG (1) | SG11202112232YA (enExample) |
| WO (1) | WO2020234432A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| WO2022198108A1 (en) * | 2021-03-18 | 2022-09-22 | Affilogic | Polypeptides for complement inhibition |
| US20250074973A1 (en) * | 2021-12-30 | 2025-03-06 | Annexon, Inc. | Compositions and methods for treating huntington’s disease |
| CA3259060A1 (en) * | 2022-07-14 | 2024-01-18 | argenx BV | DOSAGE REGIMEN FOR THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY (MMN) |
| KR20250158059A (ko) * | 2023-03-07 | 2025-11-05 | 더 클리브랜드 클리닉 파운데이션 | 인간 보체 성분 2 결합 분자 |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| KR101503540B1 (ko) * | 2006-09-05 | 2015-03-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항체 매개된 신경병증의 치료를 위한 방법과 조성물 |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| SI3028716T1 (sl) * | 2006-10-10 | 2021-01-29 | Regenesance B.V. | Komplementarna inhibicija za izboljšano regeneracijo živcev |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| CA2847862C (en) * | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| WO2014186622A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| US9944717B2 (en) * | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| CA2931090A1 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| ES3013108T3 (en) * | 2014-11-05 | 2025-04-11 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
| US11091591B2 (en) * | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| CN115260310B (zh) * | 2015-11-24 | 2025-02-25 | 安尼艾克松股份有限公司 | 抗补体因子c1q的fab片段及其应用 |
| EP3454902A4 (en) * | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| BR112019018950A2 (pt) * | 2017-03-14 | 2020-04-22 | Bioverativ Usa Inc. | métodos para tratamento de doenças e distúrbios mediados por complemento |
| US11866701B2 (en) * | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 US US17/608,637 patent/US20250066460A1/en active Pending
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 AU AU2020279543A patent/AU2020279543A1/en active Pending
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114269382B (zh) | 2024-02-23 |
| US20250066460A1 (en) | 2025-02-27 |
| LT3972643T (lt) | 2025-07-10 |
| EA202193189A1 (ru) | 2022-03-11 |
| HUE072743T2 (hu) | 2025-12-28 |
| GB201907153D0 (en) | 2019-07-03 |
| AU2020279543A1 (en) | 2021-11-25 |
| PL3972643T3 (pl) | 2025-09-08 |
| JP2022533705A (ja) | 2022-07-25 |
| JP2025038109A (ja) | 2025-03-18 |
| MA71752A (fr) | 2025-05-30 |
| PT3972643T (pt) | 2025-07-15 |
| EP3972643B1 (en) | 2025-05-14 |
| EP4570316A2 (en) | 2025-06-18 |
| KR20220010505A (ko) | 2022-01-25 |
| BR112021023198A2 (pt) | 2022-01-04 |
| JP7607590B2 (ja) | 2024-12-27 |
| JP2025041724A (ja) | 2025-03-26 |
| DK3972643T3 (da) | 2025-07-21 |
| IL288010A (en) | 2022-01-01 |
| EP4570316A3 (en) | 2025-08-13 |
| CA3138401A1 (en) | 2020-11-26 |
| SG11202112232YA (en) | 2021-12-30 |
| GB2584105B (en) | 2023-08-02 |
| CN118021970A (zh) | 2024-05-14 |
| NZ781789A (en) | 2025-03-28 |
| ES3035736T3 (en) | 2025-09-08 |
| FI3972643T3 (fi) | 2025-07-16 |
| WO2020234432A1 (en) | 2020-11-26 |
| EP3972643A1 (en) | 2022-03-30 |
| GB2584105A (en) | 2020-11-25 |
| MX2025014486A (es) | 2026-01-07 |
| CN114269382A (zh) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202193189A1 (ru) | Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий | |
| JOP20200082A1 (ar) | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول | |
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| MX2022002977A (es) | Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| EA202091640A1 (ru) | Способы лечения опосредованного il-6 воспаления без иммунодепрессии | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| MY209831A (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| MX2013014756A (es) | Metodos para tratar transtornos cronicos con inhibidores del complemento. | |
| MX2010009722A (es) | Procedimiento de tratamiento del dolor cronico. | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MY202368A (en) | Methods of treating ulcerative colitis | |
| IL285627A (en) | Systems and methods for the treatment of symptoms associated with migraines | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
| AR099707A1 (es) | Composiciones y métodos para tratar trastornos renales | |
| AR107983A1 (es) | Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1 | |
| EA201590720A8 (ru) | АНТИ-Flt-1-АНТИТЕЛА В ЛЕЧЕНИИ МЫШЕЧНОЙ ДИСТРОФИИ ДЮШЕНА | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis |